Allogeneic transplantation: A therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia

P. Mittal; R. M. Saliba; S. A. Giralt; M. Shahjahan; A. I. Cohen; S. Karandish; F. Onida; M. Beran; R. E. Champlin; M. de Lima

doi:10.1038/sj.bmt.1704472

Allogeneic transplantation: A therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia

P. Mittal, R. M. Saliba, S. A. Giralt, M. Shahjahan, A. I. Cohen, S. Karandish, F. Onida, M. Beran, R. E. Champlin, M. de Lima

Stem Cell Transplantation

Research output: Contribution to journal › Article › peer-review

73 Scopus citations

Abstract

The role of allogeneic transplantation for myeloproliferative diseases other than chronic myeloid leukemia is not well established. In all, 20 patients with a median age of 51 years underwent allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis (n = 5), chronic myelomonocytic leukemia (CMML) (n = 8) and Philadelphia (Ph) chromosome-negative/BCR-ABL-negative chronic myeloid leukemia (CML) (n = 7) in our institution. Patients who developed acute leukemia prior to HSCT were excluded from this analysis. A total of 15 patients received related and five patients received unrelated donor transplants. One patient failed to engraft. After a median follow-up of 17.5 months, actuarial survival at 2 years was 47% (95% CI 2%-67%), and disease-free survival 37% (95% CI 17-58%). Allogeneic transplantation may provide a therapeutic option for patients with myelofibrosis, CMML and Ph chromosome-negative/BCR-ABL-negative CML.

Original language	English (US)
Pages (from-to)	1005-1009
Number of pages	5
Journal	Bone marrow transplantation
Volume	33
Issue number	10
DOIs	https://doi.org/10.1038/sj.bmt.1704472
State	Published - May 2004

Keywords

CML
Chronic myelomonocytic leukemia
Myelofibrosis
Myeloproliferative diseases
Philadelphia chromosome/BCR-ABL negative

ASJC Scopus subject areas

Hematology
Transplantation

Access to Document

10.1038/sj.bmt.1704472

Cite this

Mittal, P., Saliba, R. M., Giralt, S. A., Shahjahan, M., Cohen, A. I., Karandish, S., Onida, F., Beran, M., Champlin, R. E., & de Lima, M. (2004). Allogeneic transplantation: A therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Bone marrow transplantation, 33(10), 1005-1009. https://doi.org/10.1038/sj.bmt.1704472

Mittal, P, Saliba, RM, Giralt, SA, Shahjahan, M, Cohen, AI, Karandish, S, Onida, F, Beran, M, Champlin, RE & de Lima, M 2004, 'Allogeneic transplantation: A therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia', Bone marrow transplantation, vol. 33, no. 10, pp. 1005-1009. https://doi.org/10.1038/sj.bmt.1704472

@article{ca1b3ef871eb48b48aa35ade6bc565eb,

title = "Allogeneic transplantation: A therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia",

abstract = "The role of allogeneic transplantation for myeloproliferative diseases other than chronic myeloid leukemia is not well established. In all, 20 patients with a median age of 51 years underwent allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis (n = 5), chronic myelomonocytic leukemia (CMML) (n = 8) and Philadelphia (Ph) chromosome-negative/BCR-ABL-negative chronic myeloid leukemia (CML) (n = 7) in our institution. Patients who developed acute leukemia prior to HSCT were excluded from this analysis. A total of 15 patients received related and five patients received unrelated donor transplants. One patient failed to engraft. After a median follow-up of 17.5 months, actuarial survival at 2 years was 47% (95% CI 2%-67%), and disease-free survival 37% (95% CI 17-58%). Allogeneic transplantation may provide a therapeutic option for patients with myelofibrosis, CMML and Ph chromosome-negative/BCR-ABL-negative CML.",

keywords = "CML, Chronic myelomonocytic leukemia, Myelofibrosis, Myeloproliferative diseases, Philadelphia chromosome/BCR-ABL negative",

author = "P. Mittal and Saliba, {R. M.} and Giralt, {S. A.} and M. Shahjahan and Cohen, {A. I.} and S. Karandish and F. Onida and M. Beran and Champlin, {R. E.} and {de Lima}, M.",

year = "2004",

month = may,

doi = "10.1038/sj.bmt.1704472",

language = "English (US)",

volume = "33",

pages = "1005--1009",

journal = "Bone marrow transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "10",

}

TY - JOUR

T1 - Allogeneic transplantation

T2 - A therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia

AU - Mittal, P.

AU - Saliba, R. M.

AU - Giralt, S. A.

AU - Shahjahan, M.

AU - Cohen, A. I.

AU - Karandish, S.

AU - Onida, F.

AU - Beran, M.

AU - Champlin, R. E.

AU - de Lima, M.

PY - 2004/5

Y1 - 2004/5

N2 - The role of allogeneic transplantation for myeloproliferative diseases other than chronic myeloid leukemia is not well established. In all, 20 patients with a median age of 51 years underwent allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis (n = 5), chronic myelomonocytic leukemia (CMML) (n = 8) and Philadelphia (Ph) chromosome-negative/BCR-ABL-negative chronic myeloid leukemia (CML) (n = 7) in our institution. Patients who developed acute leukemia prior to HSCT were excluded from this analysis. A total of 15 patients received related and five patients received unrelated donor transplants. One patient failed to engraft. After a median follow-up of 17.5 months, actuarial survival at 2 years was 47% (95% CI 2%-67%), and disease-free survival 37% (95% CI 17-58%). Allogeneic transplantation may provide a therapeutic option for patients with myelofibrosis, CMML and Ph chromosome-negative/BCR-ABL-negative CML.

AB - The role of allogeneic transplantation for myeloproliferative diseases other than chronic myeloid leukemia is not well established. In all, 20 patients with a median age of 51 years underwent allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis (n = 5), chronic myelomonocytic leukemia (CMML) (n = 8) and Philadelphia (Ph) chromosome-negative/BCR-ABL-negative chronic myeloid leukemia (CML) (n = 7) in our institution. Patients who developed acute leukemia prior to HSCT were excluded from this analysis. A total of 15 patients received related and five patients received unrelated donor transplants. One patient failed to engraft. After a median follow-up of 17.5 months, actuarial survival at 2 years was 47% (95% CI 2%-67%), and disease-free survival 37% (95% CI 17-58%). Allogeneic transplantation may provide a therapeutic option for patients with myelofibrosis, CMML and Ph chromosome-negative/BCR-ABL-negative CML.

KW - CML

KW - Chronic myelomonocytic leukemia

KW - Myelofibrosis

KW - Myeloproliferative diseases

KW - Philadelphia chromosome/BCR-ABL negative

UR - http://www.scopus.com/inward/record.url?scp=2942585719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942585719&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1704472

DO - 10.1038/sj.bmt.1704472

M3 - Article

C2 - 15048141

AN - SCOPUS:2942585719

SN - 0268-3369

VL - 33

SP - 1005

EP - 1009

JO - Bone marrow transplantation

JF - Bone marrow transplantation

IS - 10

ER -

Allogeneic transplantation: A therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this